On the other hand, VSV infection of tumour-associated DCs reduced their viability and prevented their migration to the draining lymph nodes to prime a tumour-specific CD8 T cell response [50], representing a disadvantage of these vectors as a tool for tumour vaccine development. Here, CD8A is linked to neoplasm.